Bob Nelsen, Anne Wo­j­ci­c­ki join $20M round for longevi­ty start­up hop­ing to slow down ag­ing of the ovary

Hav­ing helped birth some of the ear­li­est an­ti-ag­ing up­starts, Bob Nelsen has found an­oth­er new idea to love in the bur­geon­ing space.

The ARCH man­ag­ing di­rec­tor is among a syn­di­cate pour­ing $20 mil­lion of Se­ries A cash in­to Ga­me­to, a New York-based biotech whose stat­ed mis­sion is to re­pro­gram ovar­i­an cells to slow down the ag­ing of the ovary — which is very much “ac­cel­er­at­ed” com­pared to oth­er or­gans, ac­cord­ing to the com­pa­ny.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN